The Chemours CC announces its next round of earnings Wednesday. Here's Benzinga's advanced look at Chemours' Q4 earnings report.
Earnings and Revenue
Sell-side analysts expect Chemours' EPS to be near 95 cents per share on sales of $1.55 billion.
Chemours EPS in the same period a year ago totaled 8 cents per share. Sales were $1 billion. If the company were to post earnings inline with the consensus estimate when it reports Wednesday, revenue would be up 17.25 percent from the year-ago period.
Here's how the company's reported EPS has stacked up against analyst estimates in the past:
Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
EPS Estimate | 1.03 | 0.85 | 0.5 | 0.27 |
EPS Actual | 1.12 | 0.87 | 0.75 | 0.08 |
Q4 EPS Estimate: 95 cents per share
Q4 Revenues Estimate: $1 billion
Stock Performance
Over the last 52-week period, shares are up 69.71 percent. Given that these returns are generally positive, long-term shareholders are probably content going into this earnings release.
Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. The average rating by analysts on Chemours stock is a Neutral. The strength of this rating has risen over the past 90 days.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.